Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 2002International Clinical Psychopharmacology

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160???mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

View Full Paper
Ask AI
Bookmark
Share

Authors

MAM. AratóRCR. O ConnorHMHerbert Y. Meltzer

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Arató et al. (2002) studied this question.

synapsesocial.com/papers/6a9375e52aef8ffffdabdceehttps://doi.org/10.1097/00004850-200209000-00001
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical Risk Following Abrupt and Gradual Withdrawal of Maintenance Neuroleptic Treatment1997 · 248 citations
  2. 2Compliance with antipsychotic drug treatment: influence of side effects1994 · 246 citations
  3. 3An Exploratory Haloperidol-Controlled Dose-Finding Study of Ziprasidone in Hospitalized Patients With Schizophrenia or Schizoaffective Disorder1998 · 185 citations
  4. 4A Rating Scale for Drug-Induced Akathisia1989 · 2,189 citations
  5. 5Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis1999 · 2,399 citations